Logo Logo

Publications by Zinzani, Pier Luigi

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 7.

Journal article

Dreyling, Martin; Santoro, Armando; Mollica, Luigina; Leppä, Sirpa; Follows, George; Lenz, Georg; Kim, Won Seog; Nagler, Arnon; Dimou, Maria; Demeter, Judit; Özcan, Muhit; Kosinova, Marina; Bouabdallah, Krimo; Morschhauser, Franck; Stevens, Don A.; Trevarthen, David; Munoz, Javier; Rodrigues, Liana; Hiemeyer, Florian; Miriyala, Ashok; Garcia‐Vargas, Jose; Childs, Barrett H.; Zinzani, Pier Luigi (2020): Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study. In: American Journal of Hematology, Vol. 95, No. 4: pp. 362-371 [PDF, 1MB]

Zinzani, Pier Luigi; Flinn, Ian W.; Yuen, Sam L. S.; Topp, Max S.; Rusconi, Chiara; Fleury, Isabelle; Le Du, Katell; Arthur, Christopher; Pro, Barbara; Gritti, Giuseppe; Crump, Michael; Petrich, Adam; Samineni, Divya; Sinha, Arijit; Punnoose, Elizabeth A.; Szafer-Glusman, Edith; Spielewoy, Nathalie; Mobasher, Mehrdad; Humphrey, Kathryn; Kornacker, Martin; Hiddemann, Wolfgang (2020): Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. In: Blood, Vol. 136, No. 23: pp. 2628-2637

Zinzani, Pier Luigi; Dreyling, Martin; Gradishar, William; Andre, Marc; Esteva, Francisco J.; Boulos, Suliman; Barca, Eva Gonzalez; Curigliano, Giuseppe (2019): Are Biosimilars the Future of Oncology and Haematology? In: Drugs, Vol. 79, No. 15: pp. 1609-1624

Morschhauser, Franck; Flinn, Ian W.; Advani, Ranjana; Sehn, Laurie H.; Diefenbach, Catherine; Kolibaba, Kathryn; Press, Oliver W.; Salles, Gilles; Tilly, Herve; Chen, Andy I.; Assouline, Sarit; Cheson, Bruce D.; Dreyling, Martin; Hagenbeek, Anton; Zinzani, Pier Luigi; Jones, Surai; Cheng, Ji; Lu, Dan; Penuel, Elicia; Hirata, Jamie; Wenger, Michael; Chu, Yu-Waye; Sharman, Jeff (2019): Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). In: Lancet Haematology, Vol. 6, No. 5, E254-E265

Dreyling, Martin; Aurer, Igor; Cortelazzo, Sergio; Hermine, Olivier; Hess, Georg; Jerkeman, Mats; Le Gouill, Steven; Ribrag, Vincent; Trneny, Marek; Visco, Carlo; Walewski, Jan; Zaja, Francesco; Zinzani, Pier Luigi (2018): Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. In: Leukemia & Lymphoma, Vol. 59, No. 8: pp. 1814-1828

Dreyling, Martin; Santoro, Armando; Mollica, Luigina; Leppä, Sirpa; Follows, George A.; Lenz, Georg; Kim, Won Seog; Nagler, Arnon; Panayiotidis, Panayiotis; Demeter, Judit; Özcan, Muhit; Kosinova, Marina; Bouabdallah, Krimo; Morschhauser, Franck; Stevens, Don A.; Trevarthen, David; Giurescu, Marius; Cupit, Lisa; Liu, Li; Köchert, Karl; Seidel, Henrik; Pena, Carol; Yin, Shuxin; Hiemeyer, Florian; Garcia-Vargas, Jose; Childs, Barrett H.; Zinzani, Pier Luigi (2017): Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. In: Journal of Clinical Oncology, Vol. 35, No. 35: pp. 3898-3910

Cheson, Bruce D.; Brugger, Wolfram; Damaj, Gandhi; Dreyling, Martin; Kahl, Brad; Kimby, Eva; Ogura, Michinori; Weidmann, Eckhart; Wendtner, Clemens-Martin; Zinzani, Pier Luigi (2016): Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update. In: Leukemia & Lymphoma, Vol. 57, No. 4: pp. 766-782

This list was generated on Mon Jan 30 05:12:39 2023 CET.